Literature DB >> 15539514

Establishing phenotypic features associated with morbidity in human T-cell lymphotropic virus type 1 infection.

G E A Brito-Melo1, J G Souza, E F Barbosa-Stancioli, A B F Carneiro-Proietti, B Catalan-Soares, J G Ribas, G W Thorum, R D R Rocha, O A Martins-Filho.   

Abstract

The human T-cell lymphotropic virus type 1 (HTLV-1) is the causative agent of HTLV-1-associated myelopathy/tropical spastic paraparesis (HT). Although it is widely believed that virus infection and host immune response are involved in the pathogenic mechanisms, the role of the immune system in the development and/or maintenance of HT remains unknown. We performed an analysis of the peripheral blood leukocyte phenotype for two different subcohorts of HTLV-1-infected individuals to verify the existence of similar immunological alterations, possible laboratory markers for HT. The leukocyte population balance, the activation status of the T lymphocytes, and the cellular migratory potential of T lymphocytes, monocytes, and neutrophils were evaluated in the peripheral blood of HTLV-1-infected individuals classified as asymptomatic individuals, oligosymptomatic individuals, and individuals with HT. Data analysis demonstrated that a decreased percentage of B cells, resulting in an increased T cell/B cell ratio and an increase in the CD8+ HLA-DR+ T lymphocytes, exclusively in the HT group could be identified in both subcohorts, suggesting its possible use as a potential immunological marker for HT for use in the laboratory. Moreover, analysis of likelihood ratios showed that if an HTLV-1-infected individual demonstrated B-cell percentages lower than 7.0%, a T cell/B cell ratio higher than 11, or a percentage of CD8+ HLA-DR+ T lymphocytes higher than 70.0%, this individual would have, respectively, a 12-, 13-, or 22-times-greater chance of belonging to the HT group. Based on these data, we propose that the T cell/B cell ratios and percentages of circulating B cells and activated CD8+ T lymphocytes in HTLV-1-infected patients are important immunological indicators which could help clinicians monitor HTLV-1 infection and differentiate the HT group from the asymptomatic and oligosymptomatic groups.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15539514      PMCID: PMC524787          DOI: 10.1128/CDLI.11.6.1105-1110.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  25 in total

Review 1.  [Pathogenetic significance of HTLV-I infection and immune surveillance in HAM].

Authors:  K Fujihara
Journal:  Rinsho Shinkeigaku       Date:  1999-01

2.  Phenotypic study of peripheral blood leucocytes in HTLV-I-infected individuals from Minas Gerais, Brazil.

Authors:  G E A Brito-Melo; O A Martins-Filho; A B F Carneiro-Proietti; B Catalan-Soares; J G Ribas; G W Thorum; E F Barbosa-Stancioli
Journal:  Scand J Immunol       Date:  2002-06       Impact factor: 3.487

3.  Flow cytometric differentiation of Asian and Western types of multiple sclerosis, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and hyperIgEaemic myelitis by analyses of memory CD4 positive T cell subsets and NK cell subsets.

Authors:  X M Wu; M Osoegawa; K Yamasaki; Y Kawano; H Ochi; I Horiuchi; M Minohara; Y Ohyagi; T Yamada; J I Kira
Journal:  J Neurol Sci       Date:  2000-08-01       Impact factor: 3.181

Review 4.  Avoiding the kiss of death: how HIV and other chronic viruses survive.

Authors:  Judy Lieberman; N Manjunath; Premlata Shankar
Journal:  Curr Opin Immunol       Date:  2002-08       Impact factor: 7.486

Review 5.  Human T cell leukemia virus type I and neurologic disease: events in bone marrow, peripheral blood, and central nervous system during normal immune surveillance and neuroinflammation.

Authors:  Christian Grant; Kate Barmak; Timothy Alefantis; Jing Yao; Steven Jacobson; Brian Wigdahl
Journal:  J Cell Physiol       Date:  2002-02       Impact factor: 6.384

6.  Blood mononuclear cells in patients with HTLV-I-associated myelopathy: lymphocytes are highly activated and adhesion to endothelial cells is increased.

Authors:  A Al-Fahim; P Cabre; L Kastrukoff; K Dorovini-Zis; J Oger
Journal:  Cell Immunol       Date:  1999-11-25       Impact factor: 4.868

Review 7.  Immunopathogenesis of human T cell lymphotropic virus type I-associated myelopathy.

Authors:  M Nagai; S Jacobson
Journal:  Curr Opin Neurol       Date:  2001-06       Impact factor: 5.710

8.  Frequent reversible membrane damage in peripheral blood B cells in human T cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Authors:  Y Furukawa; C R Bangham; G P Taylor; J N Weber; M Osame
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

9.  Interactions between brain endothelial cells and human T-cell leukemia virus type 1-infected lymphocytes: mechanisms of viral entry into the central nervous system.

Authors:  I A Romero; M C Prevost; E Perret; P Adamson; J Greenwood; P O Couraud; S Ozden
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

10.  Ancient HTLV type 1 provirus DNA of Andean mummy.

Authors:  S Sonoda; H C Li; L Cartier; L Nunez; K Tajima
Journal:  AIDS Res Hum Retroviruses       Date:  2000-11-01       Impact factor: 2.205

View more
  3 in total

1.  IL-10 produced by CD4+ and CD8+ T cells emerge as a putative immunoregulatory mechanism to counterbalance the monocyte-derived TNF-alpha and guarantee asymptomatic clinical status during chronic HTLV-I infection.

Authors:  G E A Brito-Melo; V Peruhype-Magalhães; A Teixeira-Carvalho; E F Barbosa-Stancioli; A B F Carneiro-Proietti; B Catalan-Soares; J G Ribas; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

2.  Human T lymphotropic virus type 1 (HTLV-1) proviral load induces activation of T-lymphocytes in asymptomatic carriers.

Authors:  Raimundo Coutinho; Maria Fernanda Rios Grassi; Ana Beatriz Korngold; Viviana Nilla Olavarria; Bernardo Galvão-Castro; Rita Elizabeth Mascarenhas
Journal:  BMC Infect Dis       Date:  2014-08-22       Impact factor: 3.090

3.  CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis.

Authors:  Soraya Maria Menezes; Daniele Decanine; David Brassat; Ricardo Khouri; Saul V Schnitman; Ramon Kruschewsky; Giovanni López; Carolina Alvarez; Michael Talledo; Eduardo Gotuzzo; Anne-Mieke Vandamme; Bernardo Galvão-Castro; Roland Liblau; Johan Van Weyenbergh
Journal:  J Neuroinflammation       Date:  2014-01-29       Impact factor: 8.322

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.